November 24, 2021
Watch for 1 minute
Source / information
Published by:
Source:
Allegretti JR, et al. CP101, an orally administered microbiome therapeutic in the trial phase, increases the diversity of the gut microbiome and prevents recurrent C. difficile infection: results of a randomized, placebo-controlled study. Presented at: ACG Annual Scientific Meeting; 22.-27. October 2021; Las Vegas (hybrid meeting).
Disclosure:
Foster does not report any relevant financial information.
ADD SUBJECT TO EMAIL ALERTS
Receive an email when new articles are published on
Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe
We could not process your request. Please try again later. If this problem persists, please contact [email protected].
Back to Healio
In this video, C. Jonathan D. Foster, DO, FACOI, discusses the results of the PRISM3 study evaluating CP101, an investigational microbiome therapeutic, for recurrent Clostridioides difficile infections.
The randomized, double-blind, placebo-controlled PRISM3 study presented at the ACG Annual Scientific Meeting demonstrated that CP101 had its primary endpoint of sustained clinical cure, defined as the absence of a C. difficile relapse after 8 weeks with no serious treatment-related side effects .
Foster, medical director of gastroenterology and advanced endoscopy at Jefferson Health New Jersey, stated that these were “excellent data for the future,” adding that this treatment is particularly relevant during the COVID-19 era.
“Given the COVID-19 problem and the decreased availability of stool transplants, we need an FDA-approved oral drug to prevent recurrence of C. difficile infection, in addition to the antibiotics currently available,” said Foster. “We look forward to the Phase 3 clinical trial and the future of this drug, and hope that one day it will be approved for use in the US and Europe.”
ADD SUBJECT TO EMAIL ALERTS
Receive an email when new articles are published on
Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe
We could not process your request. Please try again later. If this problem persists, please contact [email protected].
Back to Healio
